$26.81
0.71[2.72%]
At close: Apr 23
$26.81
0[0.00%]
After Hours: 4:00PM EDT
Pacira BioSciences
(NASDAQ:PCRX)Pacira BioSciences Stock (NASDAQ:PCRX), Analyst Ratings, Price Targets, Predictions
Pacira BioSciences Inc has a consensus price target of $58.75, established from looking at the 51 latest analyst ratings. The last 3 analyst ratings were released from Needham, JP Morgan, and HC Wainwright & Co. on April 9, 2024, March 7, 2024, and March 4, 2024. With an average price target of $49 between Needham, JP Morgan, and HC Wainwright & Co., there's an implied 82.77% upside for Pacira BioSciences Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
JP Morgan
HC Wainwright & Co.
RBC Capital
Wedbush
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Pacira BioSciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/09/2024 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 67.85% | Needham | Serge Belanger | → $45 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2024 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 67.85% | JP Morgan | Hardik Parikh | → $45 | Assumes | → Overweight | Get Alert |
| 03/04/2024 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 112.61% | HC Wainwright & Co. | Oren Livnat | → $57 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 67.85% | RBC Capital | Gregory Renza | $53 → $45 | Maintains | Outperform | Get Alert |
| 03/01/2024 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 67.85% | Needham | Serge Belanger | → $45 | Reiterates | Buy → Buy | Get Alert |
| 02/08/2024 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 112.61% | Wedbush | Andreas Argyrides | → $57 | Reiterates | Outperform → Outperform | Get Alert |
| 12/20/2023 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 56.66% | Raymond James | Gary Nachman | → $42 | Initiates | → Outperform | Get Alert |
| 11/06/2023 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 112.61% | HC Wainwright & Co. | Oren Livnat | $63 → $57 | Maintains | Buy | Get Alert |
| 11/03/2023 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 56.66% | Piper Sandler | David Amsellem | $50 → $42 | Maintains | Overweight | Get Alert |
| 11/03/2023 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 116.34% | RBC Capital | Gregory Renza | $67 → $58 | Maintains | Outperform | Get Alert |
| 11/03/2023 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 67.85% | Needham | Serge Belanger | $52 → $45 | Maintains | Buy | Get Alert |
| 10/23/2023 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 112.61% | Barclays | Balaji Prasad | $60 → $57 | Maintains | Overweight | Get Alert |
| 10/03/2023 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 153.64% | RBC Capital | Gregory Renza | → $68 | Reiterates | Outperform → Outperform | Get Alert |
| 08/03/2023 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 86.5% | Piper Sandler | David Amsellem | $60 → $50 | Maintains | Overweight | Get Alert |
| 08/03/2023 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 105.15% | Truist Securities | Les Sulewski | $60 → $55 | Maintains | Buy | Get Alert |
| 08/03/2023 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 153.64% | RBC Capital | Gregory Renza | $70 → $68 | Maintains | Outperform | Get Alert |
| 08/03/2023 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 86.5% | TD Cowen | Boris Peaker | → $50 | Upgrade | Market Perform → Outperform | Get Alert |
| 08/03/2023 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 134.99% | HC Wainwright & Co. | Oren Livnat | $68 → $63 | Maintains | Buy | Get Alert |
| 08/03/2023 | PCRX | Buy Now | Pacira BioSciences | $26.81 | 93.96% | Needham | Serge Belanger | $60 → $52 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Pacira BioSciences (PCRX)?
The latest price target for Pacira BioSciences (NASDAQ: PCRX) was reported by Needham on April 9, 2024. The analyst firm set a price target for $45.00 expecting PCRX to rise to within 12 months (a possible 67.85% upside). 24 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pacira BioSciences (PCRX)?
The latest analyst rating for Pacira BioSciences (NASDAQ: PCRX) was provided by Needham, and Pacira BioSciences reiterated their buy rating.
When was the last upgrade for Pacira BioSciences (PCRX)?
The last upgrade for Pacira BioSciences Inc happened on August 3, 2023 when TD Cowen raised their price target to $50. TD Cowen previously had a market perform for Pacira BioSciences Inc.
When was the last downgrade for Pacira BioSciences (PCRX)?
There is no last downgrade for Pacira BioSciences.
When is the next analyst rating going to be posted or updated for Pacira BioSciences (PCRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pacira BioSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pacira BioSciences was filed on April 9, 2024 so you should expect the next rating to be made available sometime around April 9, 2025.
Is the Analyst Rating Pacira BioSciences (PCRX) correct?
While ratings are subjective and will change, the latest Pacira BioSciences (PCRX) rating was a reiterated with a price target of $0.00 to $45.00. The current price Pacira BioSciences (PCRX) is trading at is $26.81, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.